Exceptional Survival Data, Lower Costs Key to the Competitive Advantage of DCVax®

Press releases may be edited for formatting or style | June 16, 2010

* If DCVax®-Brain and DCVax®-Prostate are successful in their respective pivotal trials and eventually approved, then we see both products as having potential blockbuster sales. More importantly there are other key advantages to NWBT's technology which have not yet been appreciated by the market. This includes clear manufacturing advantages offered by NWBTs single-batch bulk manufacturing process (which will be automated in the future using a proprietary, patent protected manufacturing process), and by its high dendritic cell purity of the final vaccine and crucially what we believe is a stronger patent position for DCVax®-Prostate than for Provenge outside of the US.

About Northwest Biotherapeutics
Northwest Biotherapeutics (OTCBB:NWBO) is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies, with a concerted focus on the development of its dendritic cell-based immunotherapy. The Company's lead clinical trial is a 240 patient double blind, randomized, placebo controlled Phase II trial in GBM. Northwest Biotherapeutics has also received clearance from the FDA for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also conducted a Phase I/II trial with DCVax for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage. Further Company, product and clinical site information may be accessed online at http://www.nwbio.com/.

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

--

Summary Of Matrix Group Report On Cancer Vaccines And Northwest Biotherapeutics: "Competitive Advantage In Cancer Vaccines"

Northwest Biotherapeutics (NWBT) is a US cancer vaccine maker, which, like Dendreon, operates in the personalized immunotherapy cancer space using cutting-edge dendritic cell technology. NWBT currently has two vaccines at or near late-stage development in glioblastoma (brain cancer) and prostate cancer. To date the survival data from using the NWBT technology in prostate cancer has been exceptional. If DCVax®-Brain and DCVax®-Prostate are successful in their respective late stage trials and eventually approved, we see the potential for blockbuster sales for both products.